Jane Street
ATNM icon

Jane Street’s Actinium Pharmaceuticals ATNM Stock Holding History

Jane Street’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18,700
Closed -$199K – 8990
2022
Q4 		$199K Buy
+18,700
New +$190K ﹤0.01% 7672

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's ATNM Position: Q1 2026 in Review

Jane Street reduced its Actinium Pharmaceuticals (ATNM) stake by 63% in Q1 2026, selling an estimated $70K and leaving 34,299 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #11082.

Jane Street first reported a position in ATNM in Q2 2015 and has held it in 14 quarters since. The position peaked at $1.17M in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Jane Street held 34,299 shares of Actinium Pharmaceuticals worth $34.1K as of Q1 2026.
  • Jane Street sold 58,893 Actinium Pharmaceuticals shares in Q1 2026, an estimated $70K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11082 holding.
  • Jane Street first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 14 quarters since.
  • Jane Street's Actinium Pharmaceuticals position peaked at $1.17M in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.